%D8%A3%D9%88%D9%84%D8%A7%D9%86%D8%B2%D8%A7%D8%A8%D9%8A%D9%86%D8%A7%D9%84%D8%A7%D9%86%D8%B2%D8%A7%D9%BE%DB%8C%D9%86Category:OlanzapineOlanzapineOlanzapinOlanzapinOlanzapineOlanzapinoOlanzapinaOlansapiin%D8%A7%D9%84%D8%A7%D9%86%D8%B2%D8%A7%D9%BE%DB%8C%D9%86OlantsapiiniOlanzapine%D7%90%D7%95%D7%9C%D7%A0%D7%96%D7%90%D7%A4%D7%99%D7%9FOlanzapinOlanzapina%E3%82%AA%E3%83%A9%E3%83%B3%E3%82%B6%E3%83%94%E3%83%B3%EC%98%AC%EB%9E%80%EC%9E%90%ED%95%80OlanzapinumOlanzapineOlanzapin%E0%AC%93%E0%AC%B2%E0%AC%BE%E0%AC%9E%E0%AD%8D%E0%AC%9C%E0%AC%BE%E0%AC%AA%E0%AC%BF%E0%AC%A8OlanzapinaOlanzapinaOlanzapin%C4%83%D0%9E%D0%BB%D0%B0%D0%BD%D0%B7%D0%B0%D0%BF%D0%B8%D0%BDOlanzapinOlanzapineOlanzapinOlanzapinOlanzapin%D0%9E%D0%BB%D0%B0%D0%BD%D0%B7%D0%B0%D0%BF%D1%96%D0%BDOlanzapineQ201872%E5%A5%A5%E6%B0%AE%E5%B9%B3
about
5-hydroxytryptamine receptor 2ADopamine receptor D25-hydroxytryptamine receptor 2C5-hydroxytryptamine receptor 75-hydroxytryptamine receptor 65-hydroxytryptamine receptor 1A5-hydroxytryptamine receptor 1D5-hydroxytryptamine receptor 1E5-hydroxytryptamine receptor 1F5-hydroxytryptamine receptor 1BHistamine receptor H1
P129
Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility StudySafety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With SchizophreniaA Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With SchizophreniaEffects of Modafinil on Olanzapine Weight GainAntipsychotic Polypharmacy in SchizophreniaA Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I DisorderOlanzapine in Patients With Advanced Cancer and Weight LossWeight Gain Management in Patients With SchizophreniaAssessment of a Weight Management Program for Weight Gain in Patients With SchizophreniaComparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With SchizophreniaExamining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With SchizophreniaOlanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I DepressionOlanzapine Versus Comparator in the Treatment of Bipolar DisorderManaging Acute Schizophrenia, a Comparison Between Two Atypical AntipsychoticsA Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight GainStudy to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine TreatmentComparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective DisorderModulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological TherapyLarge Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)Diabetes in Neuropsychiatric DisordersA Study of Zonisamide to Prevent Olanzapine-Associated Weight GainSide Effects of Antipsychotic MedicationsBioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed ConditionBioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fasting ConditionBioequivalence Study of Olanzapine Tablets, 5 mg Under Fed StudyBioequivalence Study of Olanzapine Tablets, 5 mg of Dr. Reddy's Under Fasting ConditionsBioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fed ConditionBioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fasting ConditionNeurobiology of Eating Disorders TreatmentsSubcutaneous Olanzapine for Hyperactive or Mixed DeliriumMelatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With OlanzapineAn Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.Olanzapine Treatment of Patients With Bipolar I DisorderUse of Galantamine and CDP-choline (Citicoline) to Treat Adults With SchizophreniaA Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic SyndromeSertindole in Asian Patients With SchizophreniaIntranasal Insulin and Olanzapine Study in Healthy VolunteersEfficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer CareOlanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder
P4844
Q1949517-96EA8AE3-0876-4B47-AF95-3EAA3120D7D4Q2034004-4247792C-59ED-48EC-89B4-B8D43912F8F7Q21108118-C94C41A4-C9AD-423F-B398-BAC247124B1FQ21109355-5868351F-42DC-4814-84E8-FA58B6F7EC39Q21109363-B5181D6F-F260-48EE-9114-BAEA7030B24DQ21115043-8ED0A006-BDC9-4AA8-9BBD-313F4EA59EE6Q21115046-116C1EAB-4E23-4143-9875-F1A75F799279Q21115051-E237D2C7-4981-4FC1-A4F6-143E8A576D2AQ21115052-2E0120A1-C49A-4C6D-98D5-8FA9F3422579Q288797-FF03E799-B25D-4821-B06D-FC0D165478A3Q309513-C46DB1FE-A0F6-4F45-9C47-54FF9D69FFDC
P129
Q12135-ECE40A7C-0E82-4D76-B2A4-EBDFC6905AE4Q131755-373E2C52-61A1-4DE6-90D6-B9F26CEDB998Q154430-4918EB2B-E84C-4A31-86CD-C8627DF7F598Q170082-FE2C1E61-6819-4617-BFFB-1FEC53C7F6BDQ178190-3636C51B-286F-462A-9227-66EF6BA2C4B3Q1869874-5973DE1D-758F-4FA5-ADD4-AA4311DC9ECEQ188638-4FC7E379-9D24-4405-9FBF-22A6AFE2010DQ2157462-5B6E3ABC-8F06-468C-BD96-F16B14FBDACAQ41112-00D177F7-E6ED-4CC2-9C2A-9DB43A71E626Q544006-6E728EB9-229B-4FC3-9854-F71D08EB7442Q54972453-E68B1D9F-5D47-4870-9309-0D37C082FE38Q83030-21F81EDC-5B80-45E9-96DD-D8E498FA1ADEQ834047-BD5CA854-31AC-4149-99CA-0B19D1A85E5B
P2176
Q29006251-D3F3732B-DED5-42BC-8918-6873085818ABQ29006252-597E4AF3-977D-4A36-B3E1-89BC80E29248Q29006254-3D90695C-729F-4A1B-8CD1-0C3C70EB2109Q29006255-73D858C3-1536-416A-B7F0-0500CA5B8041Q29006257-DB592E79-D21A-4774-8722-9DDB7B0F2616Q29006258-907D6214-678B-4B7E-B12B-B65CF287C972Q29006259-8B42A78D-7F5B-4D0A-B059-145C00E4B2D0Q29006261-A35C2770-0C74-46B6-8825-D5DA3673BD8FQ29006262-39A16773-AE0C-4F9A-A198-09B5FED580E3Q29006712-1186B522-20B0-4C5E-8A41-5D3C054D0DC8Q29006767-B8F6BA64-9C3F-420D-9B42-80EAF3419EE0Q29006768-EFCB2078-1670-4116-94D6-669D5CF96752
P3781
description
Olanzapina-jaka jest maksymalna dzienna dawka? związek chemiczny
@pl
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
name
Olansapiin
@et
Olantsapiini
@fi
Olanzapin
@de
Olanzapin
@hu
Olanzapin
@nb
Olanzapin
@sh
Olanzapin
@sv
Olanzapin
@tr
Olanzapina
@es
Olanzapina
@it
type
label
Olansapiin
@et
Olantsapiini
@fi
Olanzapin
@de
Olanzapin
@hu
Olanzapin
@nb
Olanzapin
@sh
Olanzapin
@sv
Olanzapin
@tr
Olanzapina
@es
Olanzapina
@it
altLabel
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
@cy
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
@en
LY-170053
@cy
LY-170053
@en
Olanzapin
@cy
Olanzapin
@en
Olanzapina
@cy
Olanzapina
@en
Olanzapine
@en
Olanzapinum
@cy
prefLabel
Olansapiin
@et
Olantsapiini
@fi
Olanzapin
@de
Olanzapin
@hu
Olanzapin
@nb
Olanzapin
@sh
Olanzapin
@sv
Olanzapin
@tr
Olanzapina
@es
Olanzapina
@it